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SUMMARY
Human mutations in the cardiac transcription factor gene TBX5 cause Congenital Heart Disease 
(CHD), however the underlying mechanism is unknown. We report characterization of the 
endogenous TBX5 cardiac interactome and demonstrate that TBX5, long considered a 
transcriptional activator, interacts biochemically and genetically with the Nucleosome Remodeling 
and Deacetylase (NuRD) repressor complex. Incompatible gene programs are repressed by TBX5 
in the developing heart. CHD missense mutations that disrupt the TBX5-NuRD interaction cause 
depression of a subset of repressed genes. Furthermore, the TBX5-NuRD interaction is required 
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for heart development. Phylogenetic analysis showed that the TBX5-NuRD interaction domain 
evolved during early diversification of vertebrates, simultaneous with the evolution of cardiac 
septation. Collectively, this work defines a TBX5-NuRD interaction essential to cardiac 
development and the evolution of the mammalian heart, and when altered may contribute to 
human CHD.
 INTRODUCTION
Congenital malformations, or structural birth defects, are the leading cause of infant 
mortality in the US and Europe (Dolk et al., 2010; Heron and Tejada-Vera, 2009). 
Congenital heart disease (CHD) remains the most common congenital malformation, with 
atrial septal defects (ASD) present in 116 per 100,000 live births and ventricular septal 
defects (VSD) present in 307 per 100,000 live births (Gittenberger-de Groot et al., 2014). 
Holt Oram Syndrome (HOS) is an autosomal disorder associated with cardiac septal defects 
and is caused by dominant mutations in the T-box transcription factor Tbx5 (Basson et al., 
1997; Basson et al., 1994; Basson et al., 1999; Cross et al., 2000; Holt and Oram, 1960; Li et 
al., 1997). Mice heterozygous for a null mutation in Tbx5 display many of the phenotypic 
abnormalities of CHD, while mice homozygous for a null mutation in Tbx5 die by E10.5 
due to cardiac defects (Bruneau et al., 1999; Bruneau et al., 2001; Moskowitz et al., 2007; 
Moskowitz et al., 2004). In addition to its role in cardiogenesis, Tbx5 is one of the key 
factors essential for cellular reprogramming of fibroblasts into induced cardiomyocytes (Ieda 
et al., 2010; Qian et al., 2012).
While Tbx5 is an essential transcription factor for heart development and reprogramming, 
and its disease relevance is well established, there are many critical unanswered questions 
about the mechanism of TBX5 function. In particular, the TBX5 interactome has not been 
defined in-vivo, leaving unanswered the question of how TBX5 interacting proteins regulate 
TBX5's choice of distinct transcriptional targets, or how these interactions function to 
activate and/or repress target gene transcription. It is also not known how these events, when 
disrupted, contribute to CHD. To these ends, we initiated a directed proteomic-based 
approach to identify endogenous cardiac proteins that function in physical association with 
TBX5.
We report the discovery that TBX5 interacts biochemically and genetically with the 
transcriptional repression machinery of the Nucleosome Remodeling and Deacetylase 
(NuRD) complex to repress inappropriate expression of gene programs in the developing 
heart. We have further uncovered a domain of TBX5 that forms an α-Helix; we show that 
TBX5 missense mutations associated with septal defects in human patients map to this 
domain. Furthermore, HOS patient mis-sense mutations in this domain disrupt the TBX5-
NuRD interaction and elicit misexpression of inappropriate gene programs that are normally 
repressed by TBX5. Through phylogenetic analysis across numerous vertebrate species, we 
find that the NuRD-interaction domain of TBX5, and hence the interaction of TBX5 with 
NuRD, evolved during the early diversification of vertebrates, simultaneous with the 
evolution of cardiac septation. Thus, the TBX5-NuRD interaction identified here plays a 
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central role in both cardiac development and human congenital heart defects, as well as the 
evolution of the mammalian heart.
 RESULTS
 Generation of the Tbx5Avi allele
Past attempts to isolate endogenous T-box protein complexes have been hampered by their 
relative low abundance and insolubility. Therefore, we introduced an Avitag epitope into the 
murine Tbx5 locus via homologous recombination to generate a Tbx5Avi allele (Figure 1A–
D). The Avitag is a small peptide tag that is biotinylated in the presence of the bacterial 
enzyme BirA. Thus, the Avitag/BirA system combines minimal structural invasiveness with 
the specificity and strength of the biotin-streptavidin interaction, the strongest noncovalent 
peptide-ligand interaction identified to date (Bayer and Wilchek, 1980; Maine et al., 2010; 
Roesli et al., 2006; van Werven and Timmers, 2006; Wang et al., 2006); Tbx5Avi mice were 
mated to mice ubiquitously expressing BirA (Rosa26BirA) (Driegen et al., 2005). The 
Tbx5Avi; Rosa26BirA compound homozygous mice show no overt phenotype, have no 
cardiac phenotype, and are fertile. Thus, the Avitag appears to have no effect on TBX5 
activity, and expression of biotinylated TBX5Avi is not deleterious to embryonic 
development.
 Isolation and characterization of the endogenous TBX5 interactome
To define the TBX5 cardiac interactome, we performed mass spectrometry analysis of 
affinity-purified TBX5 complexes from Tbx5Avi/Avi;Rosa26BirA/BirA cardiac nuclei (Figure 
1E). We used an unbiased gene ontology-based bioinformatics classification to screen the 
functions of proteins associated with TBX5 at a statistical relevance versus Tbx5Avi/Avi 
alone (no BirA) and Rosa26BirA/BirA alone. This analysis defined a subset of 58 candidate 
interactions (Table S1). We analyzed these candidates by functional network analysis; 
drawing upon the STRING database of protein-protein interactions, 40 out of the 58 
candidates were assigned to a single interconnected network (Figure 1F, S1A).
 TBX5 interacts with components of the Nucleosome Remodeling and Deacetylase 
(NuRD) complex in vivo
Analysis of the TBX5 interaction network identified the Heterodimeric Facilitates 
Chromatin Transcription (FACT) complex and several members of the transcription 
initiation factor TFIID complex, both of which play roles in RNA Pol II-dependent gene 
transcription (Berk, 1999; Saunders et al., 2003) (Figure 1F). TBX5 has been long 
considered to be a cardiac transcriptional activator. Surprisingly, in our analysis we 
identified TBX5 in association with multiple components of the NuRD chromatin-
modifying complex (Figure 1F, G), which in most instances functions to repress gene 
transcription (Wade et al., 1998; Xue et al., 1998). We find TBX5 in association with six 
components of the NuRD transcriptional repression complex: CHD4, MTA1, RBBP4, 
GATAD2a, GATAD2b, and HDAC2. All the components required for a functional NuRD 
complex were identified in association with TBX5, as CHD3 commonly acts in a mutually 
exclusive manner with CHD4, RBBP7 and RBBP4 act redundantly, and an additional 
component of the NuRD complex, MBD3, has been suggested to be dispensable for 
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transcription factor recruitment (e.g., by hunchback (Kehle et al., 1998). We confirmed the 
interaction of TBX5 with multiple members of the NuRD complex in adult cardiac nuclear 
extracts (Figure 1G).
As TBX5 has been shown to be required for cardiogenesis at E9.5 (Bruneau et al., 2001), we 
established expression of components of the NuRD complex in cardiac tissue at E9.5. We 
found that members of the NuRD complex are strongly expressed in the heart at this stage 
by RT-PCR (Figure S1B). We further demonstrate that endogenous TBX5 (untagged TBX5) 
interacts with CHD4 at E9.5 (Figure 1H).
 TBX5 and MTA1 and cardiac septation
To assess whether the TBX5-NuRD complex interaction was physiologically relevant, we 
analyzed mutant alleles of Tbx5 and a central component of the NuRD complex, Mta1, for a 
genetic interaction (Figure 2, S2). At E13.5, Mta1+/− mice have no apparent cardiac defects 
(Figure 2C). Tbx5+/− mice exhibit partially penetrant cardiac defects as previously 
described, including ASD, VSD, and complete common atrioventricular canal (CCAVC), 
which includes both ASD and VSD components (Figure 2D) (Baban et al., 2014; Basson et 
al., 1994; Basson et al., 1999; Benson et al., 1996; Bruneau et al., 1999; Bruneau et al., 
2001; McDermott et al., 2005). Tbx5+/−; Mta1+/− heterozygous null embryos all 
demonstrated septal defects (19/19), a higher frequency of septal defects than either single 
heterozygote alone (0/14 for Mta1+/− and 12/16 for Tbx5+/−) (p = 7.1E-9 vs. WT and p = 
0.035 vs Tbx5+/−) (Figure 2E–J). Furthermore, Mta1−/− hearts also do not have septal 
defects at this stage (Figure S3). We observed no change in the left ventricular chamber 
width or left ventricular wall thickness (Figure S2D–E) or inferior or superior cushions size 
(Figure 2F–I). To rule out a developmental delay in septation in the Tbx5+/−; Mta1+/− 
heterozygous null embryos, we examined Tbx5+/−; Mta1+/− heterozygous null embryos at 
E14.5 and consistently observe CCAVCs at this time point (Figure S2F–G). These results 
demonstrate a genetic interaction between Tbx5 and Mta1 in intro-cardiac septation 
providing genetic evidence for a role for the TBX5-NuRD interaction.
 TBX5 binds to the same consensus DNA site in activated and repressed target genes
The finding that TBX5 and NuRD complex components interact biochemically and 
genetically led us to hypothesize that TBX5 can function to repress aberrant gene expression 
in the developing heart. To test this hypothesis, we performed RNA-seq analysis and 
identified genes significantly downregulated and significantly upregulated in Tbx5 null 
verses wildtype heart tissue (Figure 3, Table S2). To determine which genes were direct 
targets of TBX5, we overlaid our data set to that of a TBX5 ChIP-seq data set (He et al., 
2011) and observe that TBX5 activates and represses sets of genes that fall into distinct 
categories (Fig. 3A–C). This finding raises the possibility that TBX5 may distinguish 
activated verses repressed target genes by binding to dissimilar DNA sequences in their 
regulatory elements. To address this possibility we performed bioinformatics analysis on a 
large scale. From our ChIP-seq data, 71,624 TBX5 peak regions were identified by 
enrichment of signal using MACS2 (Zhang et al., 2008). These peak regions demonstrated a 
significant association with genes that were differentially regulated between Tbx5 wild type 
and Tbx5−/− hearts.
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Given a large number of peaks can skew results in gene-association analyses, we varied the 
number of analyzed peaks from 10,000 to 70,000 in increments of 10,000. In every instance, 
TBX5 was significantly associated with differentially expressed genes (data not shown). We 
selected the top 40,000 peaks for subsequent analyses since the inclusion of additional peaks 
minimally increased the number of associated genes (data not shown). We identified an 
association between TBX5 and 82% of genes differentially expressed between Tbx5 wild 
type and Tbx5−/− hearts (2988 of 3634, Figure 3A). Of these genes, about half were 
activated and half were repressed by TBX5. Both groups demonstrated a statistically 
significant enrichment in TBX5 binding sites in the TBX5 ChIP-peak regions (activated 4.88 
× 10−141, repressed p = 1.29 × 10−142, KS test, Figure 3B). Genes repressed by TBX5 were 
enriched in pathways involved in cancer as well as cardiac diseases, while genes activated by 
TBX5 were enriched in pathways involved in cell cycle and DNA replication, a known 
function of TBX5 (Figure 3C) (Hatcher et al., 2001, Goetz et al., 2006).
 TBX5 acts to directly repress inappropriate expression of genes in cardiac tissue
To validate the genes putatively repressed by TBX5, we rank ordered our list of repressed 
genes based on relative change in expression between wild-type and Tbx5−/− hearts and the 
number of reads from the ChIP-seq data set (Table S3). From this rank ordered list, we 
cloned the top 15 of the ChIP peak sequence elements from 14 genes and performed 
transcriptional assays (Figure 4, S4). Of the candidate genes tested, 11 were repressed by 
TBX5. This set of genes could be divided into two categories: Casz1, Fgf11, Gad1, Kcne3, 
Kctd16, Klf4, Nxph4, Plekha2, and Sncb are expressed in neural lineages (Diez-Roux et al., 
2011; Dorr et al., 2015; Liu et al., 2011; Metz et al., 2011; Smallwood et al., 1996; Sopher et 
al., 2001; Trifonov et al., 2014; Wang et al., 2014), while Casz1, Col20a1, Fgf11, Gad1, 
Klf4, Mef2b, and Plekha2 are expressed in a divergent subset of cancers (Costantini et al., 
2009; Evans and Liu, 2008; Hu et al., 2015; Huang et al., 2013; Kimura et al., 2013; Ying et 
al., 2013). Altogether, these data suggest that TBX5 function is essential for in vivo 
transcriptional repression and prevention of ectopic expression of inappropriate gene 
programs in the heart.
 TBX5 interaction with CHD4 does not require either the CHD4 chromo domains or the 
Phd domains
CHD4 is a highly conserved protein that serves as the central catalytic core component of 
the NuRD complex (Denslow and Wade, 2007). Studies across plants and animals have 
shown that CHD4 functions through interaction with DNA binding proteins by its pair of 
chromo domains. In addition CHD4 also contains a tandem set of Phd (plant homology 
domains) and an ATPase cassette (Denslow and Wade, 2007). To gain insight into the 
mechanisms of TBX5-NuRD mediated repression, we mapped the protein interaction 
domains of TBX5 of CHD4 (Figure 5A–F). Streptavidin pulldown of TBX5 complexes 
demonstrated that an N-terminal human CHD4 region containing the pair of Phd domains 
and the pair of chromo domains was required for interaction with mouse TBX5 (Figure 5A, 
C). Surprisingly, we found CHD4 deletions of either the Phd domains or the chromo 
domains still interact with TBX5 (Figure 5D) implying that TBX5 interacts with a 
previously undefined set of residues in the amino terminal portion of CHD4.
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 TBX5 interacts with the NuRD complex through a coil-α-helix domain
In vitro based approaches have led to the identification of a number of proteins that interact 
with TBX5 through two regions of TBX5; one in the amino-terminal portion of the protein 
including the most amino-terminal portion of the T-box DNA binding domain (Brown et al., 
2005; Garg et al., 2003; Ghosh et al., 2009; Hiroi et al., 2001; Wang et al., 2011) and a 
second in the C-terminus of TBX5 containing a putative nuclear localization signal (Krause 
et al., 2004; Murakami et al., 2005). To determine if TBX5 associates with the NuRD 
complex through these regions we mapped the residues of TBX5 that was essential for 
interaction with CHD4. From these studies we found a region C-terminal to the T-box was 
necessary and sufficient for interaction with CHD4 (amino acids 238–340) (Figure 5B, E–
F). A conserved function for this region is supported by our observation that the minimal 
region of TBX5 that interacts with CHD4 is highly conserved across 48 TBX5 orthologues 
(Figure 5H).
Since the region of TBX5 that interacts with CHD4 has not been included in TBX5 crystal 
structural analysis (Stirnimann et al., 2010) we sought to determine if the region of TBX5 
that interacted with CHD4 represented a true TBX5 structural domain. We therefore 
conducted molecular 3D structural modeling of the entire TBX5 protein as well as the 
minimal region of TBX5 that we showed interacted with CHD4. Results from these analyses 
revealed that TBX5 residues 255–264 is highly predicted to form a small coil-to α-Helix 
region (Figure 5I,J). We have termed this structural-functional region of TBX5 the NuRD 
Interaction Domain (TBX5NID) (Figure 5G).
 The TBX5-NuRD interaction domain is essential for cardiac development and function in 
humans
Having demonstrated TBX5 and the NuRD complex genetically and biochemically interact, 
and having established that TBX5NID represents a true structural functional domain, we next 
determined if the interaction between TBX5 and the NuRD complex is essential for TBX5 
function. For these studies we undertook a CHD patient driven approach based on the 
observations that the vast majority of molecularly characterized TBX5 mutations associated 
with CHD are mis-sense mutations within the coding region of TBX5. Most of the CHD 
associated mutations are located within the TBX5 T-box causing either a loss of DNA 
binding or degradation by non-sense mediated decay (Fan et al., 2003a; Fan et al., 2003b; 
Mori and Bruneau, 2004). However in addition, there exists a subset of CHD-associated 
mutations that lie in the C-terminus of TBX5, outside the T-box; the resulting mutant forms 
of TBX5 are stable, nuclear localized and bind DNA. The molecular basis for these CHD-
associated mutations has been unknown.
Multiple mis-sense mutations that correspond to TBX5-associated CHD in the C-terminal 
region of TBX5 that fall within the TBX5NID including: TBX5S252I, TBX5S261C, 
TBX5V263M, TBX5K266R, and TBX5Q292R (Heinritz et al., 2005) (Figure 5G). We 
investigated the physical location of these TBX5 amino acids on the predicted NID 
structural domain and observed the amino acids align along a single interaction surface of 
the TBX5NID α-Helix (Figure 5I–J). We hypothesized the CHD mis-sense mutations in the 
TBX5NID disrupt the TBX5-CHD4 interaction.
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We tested the hypothesis that TBX5 mis-sense mutations in the TBX5NID alter the TBX5-
NuRD association. Three single mis-sense mutations within the TBX5NID (TBX5S261C, 
TBX5V263M, and TBX5K266R) each abolished the interaction between TBX5 and both 
CHD4 and MTA1, and an additional two other CHD single mis-sense mutations (TBX5S252I 
and TBX5Q292R) reduced the interactions (Figure 5K). These results suggest that disruption 
of the TBX5-NuRD complex in vivo causes cardiac abnormalities associated with HOS.
 TBX5 can repress target genes in a NuRD dependent manner
Having demonstrated that the TBX5-NuRD interaction is disrupted by CHD-associated 
mutations in the NID, we queried if repression of TBX5 target genes was NuRD dependent. 
We performed transcriptional assays and observed, of the 11 validated targets repressed by 
TBX5, Kctd16 and Mef2b fail to be repressed by TBX5 containing the CHD associated 
mutation TBX5S261C (Figure 6A–B, S5). Furthermore, TBX5S261C failed to repress 
transcription of multiple elements of the Mef2b gene (Figure 6B–D). In addition, we were 
able to ChIP CHD4 in the presence of TBX5 to these elements (Figure 6E–F). Taken 
together, these results imply the TBX5-NuRD complex is required to repress inappropriate 
gene expression in the heart and further suggest a subset of CHD mutants leads to the mis-
expression of genes including Mef2b in the developing heart.
 The TBX5-NuRD interaction arose concomitantly with the evolution of cardiac septation
Phylogenetic analysis of forty-eight TBX5 orthologues demonstrated there is complete 
conservation of the TBX5NID amino acids mutated in TBX5-associated CHD in animals 
with a septated heart (TBX5S261, TBX5V263, TBX5K266) (e.g. Xenopus to human) (Figure 
7). In contrast, orthologues of TBX5 in vertebrates that lack a septated heart (e.g. zebrafish) 
have an amino acid substitution present in human CHD patients, and furthermore, this 
substitution ablates the TBX5-NuRD interaction (Figure 5K). We hypothesized that the 
Xenopus ortholog of Tbx5 would interact with the NuRD complex, but a Xenopus Tbx5 
ortholog with zebrafish NID amino acid substitutions would fail to interact with the NuRD 
complex. To test this hypothesis we generated the K266R mutation in the Xenopus ortholog 
of Tbx5 (xTbx5K266R). We observed that while mTBX5 and xTbx5 interact with the NuRD 
complex, xTbx5K266R has a disrupted interaction with CHD4 (Figure 7B). Thus, our data 
suggested that the TBX5-NuRD interaction arose coincidentally with the evolution of 
cardiac septation and it is an essential component of an evolutionarily conserved mechanism 
for cardiac septum formation.
 DISCUSSION
Here we report the isolation and characterization of the in vivo TBX5 interactome. For over 
20 years, studies have defined TBX5 as an activator of transcription. However, our analysis 
demonstrates that TBX5 interacts biochemically and genetically with the transcriptional 
repression machinery of the NuRD complex. We further report TBX5 acts to repress 
inappropriate gene programs in cardiac tissue. We observed that only a subset of TBX5-
repressed target genes failed to be repressed by the mutation of the TBX5-NuRD interacting 
domain (e.g. HOS mutation TBX5S261C; Figure 6A–D, S5) implying that TBX5-mediated 
repression occurs in both a NuRD-dependent and NuRD-independent manner. We favor a 
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model by which TBX5 regulates growth and differentiation of cardiomyocytes in part 
through the repression of alternate lineage-specific gene regulatory networks.
To date, all other predicted TBX5 interactions have been identified through in vitro studies, 
such as GST pulldowns in bacterial or cell lysates or yeast 2-hybrid approaches (Brown et 
al., 2005; Garg et al., 2003; Ghosh et al., 2009; Hiroi et al., 2001; Wang et al., 2011)(Krause 
et al., 2004; Murakami et al., 2005). In our study we isolate and characterize the endogenous 
TBX5 interactome from cardiac tissue under physiological conditions. This in vivo isolation 
is highly significant given mutations in T-box genes are causative for over 30 human 
diseases. Though we found no evidence for and interaction with proteins previously 
identified as being associated with TBX5 (BRG1, NKX2.5, GATA4, TBX20, Myocardin, 
TAZ and BAF60C), it remains possible that these proteins interact with TBX5 at time points 
of cardiac development different from those we analyzed, or that they were not identified in 
our study for technical reasons (e.g. distinct lysis buffer conditions for different studies). 
Regarding the latter point we note that if we slightly relax the statistical cutoffs, BRG1 
(SMARCA4) (Takeuchi et al., 2011) does appear to be in complex with TBX5.
 TBX5 and cardiac septation
Our data suggest the TBX5-NuRD interaction arose coincidentally with cardiac septation. 
This hypothesis is further supported by our observations that Tbx5+/−; Mta1+/− compound 
heterozygous mice have a higher frequency of cardiac septal defects than either single 
heterozygote alone (Figure 2J). AVSDs have been reported in 18 HOS patients, and 10 have 
been characterized to date (Baban et al., 2014). Of these, 6 of the mutations lead to the 
introduction of a stop codon before the TBX5NID, and one mis-sense mutation maps within 
the TBX5NID and ablates the TBX5-NuRD interaction (Figure 5K). Thus, we find a 
correlation between the phenotype of patients displaying intracardiac septal defects and the 
specific genotype of TBX5 patient mutations that causes absent or altered TBX5NID.
 CONCLUSIONS
Our studies demonstrate that a proteomic-based approach coupled with protein modeling 
provides a powerful predictive strategy in prioritizing patient mutations. This type of 
approach should be broadly applicable to the analysis of protein complexes in any cell or 
tissue type. The power of such an approach is underscored by recent high-throughput 
sequencing studies that have led to the identification of a vast number of somatic mutations 
in coding regions of potential disease causing genes. Exploiting such large datasets has 
proved problematic because it has not been possible to determine which mutations are 
naturally occurring, non-disease associated variants and which are disease-causing. Results 
presented here demonstrate a proteomic-modeling based strategy that can serve to prioritize 
mis-sense mutations and, therefore, correlate disease associated phenotypes with specific 
mutations.
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 EXPERIMENTAL PROCEDURES
 Generation of Tbx5Avi mice
The targeting construct to create Tbx5Avi was created in collaboration with the UNC Animal 
Models Core and the UNC BAC Core (Chapel Hill). Briefly, the biotin acceptor peptide 
(Avi) targeting cassette was inserted in frame to the terminal exon of the Tbx5 gene. 
Targeted ES cells were selected and introduced into B6 mouse blastocysts. High-chimera 
males were mated with B6 females to produce F1 heterozygotes (Tbx5Avi-Neo/+). 
Incorporation of the Tbx5Avi construct was confirmed by PCR and Southern analysis (Figure 
1B), presence of Tbx5Avi mRNA confirmed by RT-PCR (Figure 1D). F1 heterozygotes were 
crossed with Sox2-Cre mice (Hayashi et al., 2002) to remove the neomycin cassette in the 
F2 generation (Figure 1C). F2 compound heterozygous mice were intercrossed to remove 
the Sox2-Cre allele and establish Tbx5Avi/Avi homozygous lines. Tbx5Avi/Avi mice were 
crossed to Rosa26BirA mice (JAX), (Driegen et al., 2005). Resultant progeny were 
intercrossed to obtain compound homozygotes. Genotyping was performed by PCR. 
Genotyping primers in Supplemental Experimental Procedures. Southern probe was 
designed to Tbx5 intron 8. Genomic DNA was digested with EcoRV or BamHI. Animal care 
and animal experiments were conducted in accordance with the Animal Care Committee at 
the University of North Carolina, Chapel Hill.
 Preparation of cardiac nuclei
Frozen hearts from 4 week old Tbx5Avi/Avi; Rosa26BirA/BirA (n=3, 2 replicates) and 
Tbx5Avi/Avi or Rosa26BirA/BirA control mice (n=3, 1 replicate per genotype) were 
homogenized using a mortar and pestle in liquid nitrogen. Nuclei were prepared as 
previously described (Franklin et al., 2011) and snap frozen in liquid N2.
 Solubilization of protein complexes
Plasmids were transfected into HEK-293 cells, harvested and lysed as previously described 
(Kaltenbrun et al., 2013). E9.5 hearts were harvested in PBS and lysed as described 
(Kaltenbrun et al., 2013). Cells and nuclear pellets were resuspended in lysis buffer (200mM 
K-HEPES pH 7.4, 1.1M KOAc, 20mM MgCl2, 1% Tween-20, 10µM ZnCl2, 10mM CaCl2, 
0.5% Triton X-100, 500 mM NaCl, 1X protease inhibitors (Roche), 1X phosphatase 
inhibitors (Sigma), optimized for TBX5 complexes. Nuclei were homogenized using a 
Polytron (Kinematica), and processed for affinity purification or immunoprecipitation as 
described (Kaltenbrun et al., 2013).
 Conjugation of magnetic beads and affinity purification
Conjugation of V5 (Invitrogen R960-CUS) or TBX5 (Aviva ARP33403-P050) antibody to 
magnetic beads (Invitrogen), and immunoisolation of protein complexes was performed as 
described (Cristea et al., 2005; Kaltenbrun et al., 2013), with following modifications for 
streptavidin-coated beads. Affinity purifications performed using streptavidin conjugated 
Dynabeads (Invitrogen) by slow rocking at RT, 30 minutes. The isolated protein complex 
was eluted for 20 min at 95°C in 40 µL (80mM NaOAc pH 9.0, 95% formamide). Western 
blots were probed with mouse anti-V5 (1:5000, Invitrogen R960-CUS), rabbit anti-CHD4 
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(1:500, Active Motif 39289), mouse anti-HDAC2 (1:1000, Abcam Ab51832), rabbit anti-
MTA1 (1:5000, Bethyl A300-280A), rabbit anti-TBX5 (1:1000, Aviva ARP33403-P050, 
using light chain-specific rabbit secondary), goat anti-TBX5 (1:500, Santa Cruz SC-17866), 
and mouse anti-GFP (1:10000, Clontech 63281).
 Mass spectrometry
Isolated protein complexes were analyzed by mass spectrometry as previously described 
(Kaltenbrun et al., 2013). Briefly, tandem mass spectra were extracted by Proteome 
Discoverer (Thermo Fisher Scientific), and all MS/MS samples were analyzed with 
SEQUEST (Thermo Fisher Scientific; version 1.2.0.208), set up to search the human and 
mouse UniProt-SwissProt protein sequence database, assuming digestion pattern with 
trypsin. Scaffold (version Scaffold_3_00_06, Proteome Software Inc., Portland, OR) was 
used to validate MS/MS-based peptide and protein identifications. Peptide sequences were 
deemed a match if they could be established at >95.0% probability as specified by the 
Peptide Prophet algorithm (Keller et al., 2002). In turn, protein identifications were deemed 
a match if they could be established at >99.0% probability by the ProteinProphet algorithm 
and have at least two sequenced peptides. Protein identifications and associated spectral 
counts were exported to Excel for further data processing.
 Interaction bioinformatics analysis
Protein identifications were filtered to exclude non-specific associations. Proteins were 
retained as specific candidates if they (1) had at least two spectral counts in both 
Tbx5Avi/Avi; Rosa26BirA/BirA replicates with at least 4 spectral counts in one replicate, and 
(2) were uniquely identified or had at least a 2.5-fold spectral count enrichment in the 
Tbx5Avi/Avi; Rosa26BirA/BirA condition versus the controls. Candidates were assigned gene 
ontology classification using the UniProt GOA annotations from within the Cytoscape (v3.2) 
platform (Cline et al., 2007). Gene symbols were submitted to the web-based STRING 
database (Franceschini et al., 2013) for interaction network analysis. Interactions with a 
combined STRING score of > 0.4 (medium confidence) were retained, exported, and further 
visualized in Cytoscape.
 RNA extraction and RT-PCR
Adult (n=2) hearts were cryolysed (2.5 min/cycle, 30 Hz, 20 cycles) in Trizol (Invitrogen) 
and RNA extracted using Trizol and purified on RNeasy columns (Qiagen). cDNA synthesis 
was performed from 0.5–1 µg of RNA using random primers and SuperScript II reverse 
transcriptase (Invitrogen). Expression levels assessed using GoTaq Green Master Mix 
(Promega) and Taq polymerase by GeneAmp PCR System (Applied Biosystems). PCR 
products were analyzed by gel electrophoresis. RT-PCR primer sequences are provided in 
supplemental Experimental Procedures.
 Transcriptional assays
ChIP peak regions from candidate genes were amplified from mouse genomic DNA and 
subcloned into the PGL3-Promoter Luciferase vector (Promega). Primer sequences in 
Supplemental Experimental Procedures. HEK-293 cells were transfected with 600ng total 
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DNA in 12 well plates using FuGene6 (Promega) and harvested 48 hours later for 
transcription assay which were performed using Dual Reporter Assay System (Promega) 
according to the manufacturer’s protocol in three biological and three technical replicates 
per assay.
 DNA constructs
Generation of the Tbx5Avi targeting construct for embryonic stem cells and generation of 
chimeric mice was performed by JrGang Chen (UNC BAC Core-Chapel Hill). Tbx5-Avi-V5 
was generated by synthesizing an oligo encoding the Avi tag (5’ ggc ctg aac gac atc ttc gag 
gct cag aaa atc gaa tgg cac gaa 3’) and subcloning it into the pcDNA3.1/V5-His TOPO 
vector (Invitrogen). Full length and truncated versions of mouse Tbx5 were then subcloned 
into pcDNA3.1-Avi-V5. pEF1α-BirA-V5-Neo was generously provided by Stuart Orkin 
(Harvard University) (Kim et al., 2009). GFP tagged full length, C-terminal, and N-terminal 
human CHD4 constructs were generously provided by Stephen Jackson (Cambridge) (Polo 
et al., 2010). Site-directed mutagenesis primers are available in Supplemental Experimental 
Procedures.
 Genetic interaction and histology
Tbx5fl/fl mice were generously provided by Jon and Christine Seidman (Harvard Medical 
School). The Tbx5+/− mouse has been reported (Bruneau et al., 2001). The Mta1+/− mouse 
line was generated by Harold Olivey (Indiana University Northwest) and generously 
provided by Eric Svensson (Novartis Institutes for Biomedial Research). All mice are in a 
mixed B6/129/SvEv/CD-1 background and experiments were performed according to a 
protocol reviewed and approved by the Institutional Animal Care and Use Committee of the 
University of Chicago, in compliance with the USA Public Health Service Policy on 
Humane Care and Use of Laboratory Animals. E13.5 and E14.5 wild type, Tbx5+/−, 
Mta1+/−, and Tbx5+/−;Mta1+/− embryos were dissected from timed matings. Embryos fixed 
in 4% PFA overnight and sent to the Human Tissue Resource Center at the University of 
Chicago for paraffin embedding, sectioning, and H&E staining. Slides were imaged on a 
Leica DM2500 microscope and QImaging Retiga 2000R 1394 Color Cooled camera. 
Mta1−/− null hearts were sectioned and prepared as previously described (Dorr et al., 2015).
 RNA-seq
Heart tube dissections were performed as described (Hoffmann et al., 2014). Briefly, E9.5 
Tbx5+/+ and Tbx5−/− heart tubes were dissected away from the body nearest the myocardial 
reflections and four heart tubes were pooled to isolate sufficient RNA. Genotypes assigned 
via PCR. Pools of tissue were mechanically homogenized in TRIzol Reagent (Invitrogen, 
Carlsbad CA) and RNA was isolated in accordance with the manufacturer’s instructions. 
RNA resuspended in water was further purified with 500 µl of 1-butanol (4 times) and 500 µl 
diethyl ether (twice) (Krebs et al., 2009). Isolated RNA underwent library preparation and 
51-bp single-ended RNA sequencing at the Genomics Core Facility at The University of 
Chicago. Briefly, mRNA was selected using an oligo-dT pulldown, and barcoded libraries 
were prepared according to Illumina's instructions accompanying the TruSeq RNA Sample 
prep kit v2 (Part# RS-122–2001). Library fragments of ~275 bps (insert plus adaptor and 
PCR primer sequences) were quantitated using the Agilent Bio-analyzer 2100 and pooled in 
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equimolar amounts. The pooled libraries were sequenced on the HiSeq2500 in Rapid Run 
Mode following the manufacturer's protocols (Invitrogen, 2013).
The raw data output from the Illumina Genome Analyzer was in phredscaled base-64 fastq 
format, representing the sequence and quality scores for each read. The single-ended 51-bp 
reads were filtered based on their quality scores using FastQC toolkit (Andrews S, 2010) , 
selecting for the 37-bp reads on the right with a minimum quality score of 35 in 75% of the 
bases of the read. The reads passing the filter were aligned to the mouse genome mm10 
assembly by Tophat (version 2.0.6) using default parameters (Kim et al., 2013). The output 
SAM files were filtered for alignment sorted, and converted to BAM files using Samtools 
(Li et al., 2009). Hit counts were estimated and normalized by both each transcript's length 
and the total yield of the sequencer using Cufflinks (version 2.1.1, default parameters and “-
p 2”) (Trapnell et al., 2012). Among all Cufflinks reported transcript abundances, the 
Fragments Per Kilobase of exon per Million fragments mapped (FPKM), values larger than 
0.125 in all samples were kept for the following statistical analysis. This filter guaranteed 
the median correlation coefficient >0.96 between any two biological replicates while kept 
~65% of all transcripts, including 11789 coding genes (Ensembl annotation, mm10, 2014 
April version). Differential expression between mutant samples (n=2) and wild types (n=4) 
was tested using Cuffdiff (v2.1.1) (Trapnell et al., 2012) Although Cuffdiff lacks power for 
designs with fewer than three replicates per group, the low variability of the two biological 
replicates in all cases (r>0.96) guarantees the statistic power of a fold change to reveal 
biologically meaningful results. All genes with an adjusted p-value less than 0.05 and the 
absolute fold change larger than 1.57 were called significant.
 Large Scale bioinformatics analysis of TBX5 binding sites
Differentially expressed genes were determined by q-value (<0.05) and status (“OK”). Those 
genes that did not meet the status threshold were given a non-significant q-value (qval=1). 
TBX5 ChIP-Seq FASTQ data was downloaded from GEO (GSE21529). Tags were filtered 
using Tag-dust (Lassmann et al., 2009) and aligned to the mouse genome (mm9) using 
bowtie (Langmead et al., 2009). Peaks were called using MACS2 (Zhang et al., 2008) with 
default parameters. Peaks were associated with differentially expressed genes and 
differential motif enrichment was determined using BETA (Wang et al., 2013) with the 
following options –-pn 40000 and –-df 0.05 –-da 1. Because BETA uses a curated database 
that lacks the TBX5 motif, TBX5 peaks associated with differentially regulated genes were 
also analyzed for motif enrichment using HOMER (Heinz et al., 2010). Genes associated 
with TBX5 regulation were then analyzed for pathway enrichment using DAVID (Huang da 
et al., 2009). The top 10 (by p-value) KEGG pathways are shown for both activated and 
repressed genes.
 Chromatin IP
HEK-293 cells were transfected with the Kctd16-Luciferase construct used in transcriptional 
assays, as well as wild type TBX5 or TBX5S261C (20 µg total DNA) using FuGene 6 
(Promega). Cells were fixed in 1% PFA for 10 minutes at RT. 10 million cells were used per 
ChIP. Cells were lysed in ChIP Buffer (50mM Tris pH 7.5, 140 mM NaCl, 1mM EDTA, 1 
mM EGTA, 0.1% sodium deoxycholate, 0.1% SDS), sonicated using a Branson 450d, 12 
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cycles, 30s/cycle (1s on, 0.5s off), 30% amplitude), and spun at top speed to isolate 
chromatin. Triton X-100 was added to 1%, and the chromatin was added to CHD4-
conjugated Protein G beads (Life Technologies) at 4°C O/N. ChIP was resumed using ChIP 
Protocol (Agilent). ChIP primer sequence is available in Supplemental Experimental 
Procedures.
 TBX5 NID Modelling
The mouse TBX5 sequence was submitted to the DisProt PONDR-FIT disorder predictor in 
order to identify disordered regions in the protein. Both the entire protein and just the NID 
region were submitted to the fold recognition server HHpred (http://
toolkit.tuebingen.mpg.de/hhpred) to determine if any suitable templates were available for 
structural modeling. A small coil-to-helical region involving residues 255-264 was predicted 
by HHpred. This region of TBX5 was modeled based on the correspondingly small region of 
the structure of the CRISPR-associated protein [PDB ID 3VZI].
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• Isolation and characterization of the endogenous cardiac TBX5 interactome.
• TBX5 interacts biochemically and genetically with the NuRD repressor 
complex.
• TBX5 represses inappropriate gene programs incompatible with cardiac 
development.
• Human TBX5 mutations alter the NuRD interaction and correlate with 
septal defects.
Waldron et al. isolate the cardiac interactome of TBX5, revealing that this transcription 
factor, implicated in congenital heart disease (CHD) and thought to be an activator, 
interacts with NuRD to represses inappropriate gene expression in the heart. CHD 
mutations disrupting the TBX5-NuRD interaction cause derepression of some of these 
genes.
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Figure 1. TBX5 interacts with the NuRD complex
(A) (Top) The Tbx5-Avi targeting cassette contains the biotin acceptor peptide (Avi) fused in 
frame to the terminal coding exon of Tbx5. Neo-neomycin resistance gene. PGK-
phosphoglycerate kinase-1 promoter. Amp-Ampicillan resistance gene. Exons colored 
brown represent untranslated exons (5’ and 3’ UTR). Exons colored orange represent the T-
box DNA binding domain. Exons colored green represent the nuclear localization signal. 
Exons colored pink represent the activation domain. (Middle) Schematic of the Tbx5 
recombined locus (Tbx5Avi-Neo) upon homologous recombination. (Bottom) Schematic of 
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the Tbx5 locus upon introduction of Cre (Tbx5Avi). (B) Southern blot of positive embryonic 
stem cell clone confirms homologous recombination. (C) Southern blot of F2 mice confirms 
removal of Neo cassette upon introduction of Cre. Samples were run on the same gel but 
were noncontiguous. (D) RT-PCR analysis of Tbx5Avi/+ adult hearts demonstrates presence 
of Tbx5Avi mRNA. (E) Overview of the isolation and characterization of the endogenous 
cardiac TBX5 interactome. (F) TBX5 transcriptional interaction network. Network nodes, 
labeled with mouse gene symbols, are candidate direct or indirect TBX5 protein interactions 
identified from affinity enrichment of biotinylated TBX5. Network edges represent known 
and/or predicted functional interactions in the STRING database. Edge thickness reflects the 
combined STRING evidence score for each binary relationship. Thicker edges represent 
increased interaction evidence. Selected transcriptional complexes within the network are 
highlighted in red dashed boxes. (G) Affinity isolation of endogenous TBX5Avi from 4 week 
cardiac nuclei confirms interaction of TBX5 with endogenous components of the NuRD 
complex. (H) Affinity isolation of TBX5 from E9.5 hearts further confirms interaction of 
TBX5 with the NuRD component CHD4 in the embryonic heart.
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Figure 2. TBX5 and the NuRD complex genetically interact
Histology (Hematoxylin and Eosin) of embryonic hearts in transverse section at E13.5 (A) 
Low magnification of a wild type heart. High magnification of (B) wild type, (C) Mta1+/−, 
(D) Tbx5+/− and, (E) Tbx5+/−; Mta1+/ hearts. Tbx5+/−; Mta1+/ hearts exhibited cardiac 
septal defects including ASD, VSD, and CCAVC (asterisk). (F–I) Histology at E13.5 
through a single Tbx5+/−; Mta1+/− heart from inferior to superior revealing ASD (G) (black 
asterisk) and VSD (red asterisk) (H, I) components of CCAVC. (J) Quantification of cardiac 
defects observed in each genotype. Fisher’s exact test showed that Tbx5+/−; Mta1+/− mice 
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demonstrated significantly more septal defects than either wild type or Tbx5+/− mice. as = 
atrial septum, ivs = intervectricular septum, la = left atrium, lv = left ventricle, ra = right 
atrium, rv = right ventricle.
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Figure 3. Analysis of TBX5 binding motifs in activated vs repressed genes
(A) Schematic overlay between TBX5 peaks (He et al., 2011) and differentially expressed 
genes between wild-type and Tbx5 null heart tissue. 2988 genes are differentially expressed 
and associated with a TBX5 peak. Inset is number of up and downregulated genes. (B) 
Activating/Repressive function prediction of TBX5 peaks. Red and purple lines represent up 
and down-regulated genes. Black dashed line represents background (static genes). Genes 
are ranked from high to low based on their regulatory potential score (RPS) determined by 
BETA. P values represent significance of up or down-regulated group relative to background 
(static genes) by Kolmogorov-Smirnov test. (C) Kegg Pathway enrichment of down-
regulated genes associated with TBX5 binding ranked by – log10(pvalue). (D) TBX5 
consensus motif (top) and top motif from de novo identification (bottom) and its presence at 
ChIP-seq peaks associated with activated or repressed genes.
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Figure 4. TBX5 functions to represses misexpression of genes in cardiac tissue
(A) Summary of fold change (RNA-seq) and ChIP-seq peak values of the 15 top rank 
ordered genes. (B–L) Gene reporter elements cloned from potential TBX5 targets in the 
presence or absence of TBX5. Transcriptional assays of target genes show TBX5 acts as a 
transcriptional repressor in 11 of 15 elements tested (additional data in Figure S4). Genes 
defined as neural are shown in red, expressed in cancer as blue, or both as purple. Graphs are 
plotted as the mean luciferase value ± SEM. Student’s two tailed t-test was used to perform 
statistical analysis. * p< 0.05 *** p < 0.001.
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Figure 5. Congenital heart disease associated mutations of TBX5 disrupt TBX5-NuRD complex 
interaction and activity
(A) Schematic of CHD4 deletion constructs. Phd= Plant homeo domain. CHD4 FL = aa 1–
1937, CHD4 N = aa 1–758, CHD4 C = aa 1183–1937, TBX5 FL = aa 1-518, TBX5 N = aa 
1–237, TBX5 C = aa 238–518. (B) Schematic of TBX5 deletion constructs. NLS = Nuclear 
Localization Signal. AD = Activation domain. (C–D) Affinity isolation of full-length TBX5-
Avi-V5 with GFP-tagged CHD4 deletions reveals that CHD4 interacts with TBX5 via 
sequences in the N-terminus of CHD4, but that the Phd and chromo domains are not 
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individually required for the TBX5-CHD4 interaction. (E–F) Affinity isolation of CHD4 
with a TBX5-Avi-V5 deletion series demonstrates TBX5 sequences aa 238–340 are both 
necessary and sufficient for interaction with CHD4. This region has been termed the NuRD 
interaction domain (NID). (G) Schematic of human TBX5 protein showing location of a 
subset of CHD associated mis-sense mutations. NID= NuRD interacting domain (aa 238–
340). (H) Sequence alignment of the TBX5NID from 48 TBX5 ortholgues. Height of letters 
is relative conservation at that residue. (I) Structural prediction of the TBX5NID shows the 
TBX5NID is comprised of a coil region followed an α-helix. (J) CHD associated mis-sense 
mutations align along a single surface of the α-helix and are predicted to disrupt protein-
protein interactions (representative residues TBX5S261, TBX5V263, and TBX5K266 shown in 
dark blue). (K) Immunoisolation of V5-tagged CHD associated mis-sense mutations of 
TBX5 probed for CHD4 and MTA1.
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Figure 6. Congenital heart disease associated mutations of TBX5 disrupt TBX5-NuRD complex 
activity
(A–D) Transcription of the regulatory regions of TBX5 target genes in response to wild type 
TBX5 (second column) or TBX5S261C (third column). Additional gene targets shown in 
Figure S7. n= 9 per transcriptional assay. Graphs are plotted as the mean luciferase value ± 
SEM. Student’s two tailed t-test was used to perform statistical analysis. *** p < 0.001. (E) 
Schematic of ChIP primer location on Kctd16 element. The T-box binding element (asterisk) 
is noted. (F) ChIP of CHD4 from cells co-transfected with Kctd16-Luciferase in the 
presence of absence of TBX5.
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Figure 7. The TBX5-NuRD interaction evolved concurrently with cardiac septation
(A) Phylogenetic comparison of TBX5 orthologues with boot-strap values. Dark green 
brackets represent animals with a septated heart. Light green brackets represent animals 
without a septated heart. Sequence of core amino acid residues required for the TBX5-
NuRD interaction are shown to the right. Amino acid residues mutated in TBX5-associated 
CHD are bolded, and a K->R substitution from fish to frog is highlighted in pink. (B) 
Immunoisolation of V5-tagged TBX5 orthologs probed for CHD4.
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